Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?

@article{Chin2015WhichPM,
  title={Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?},
  author={Paul Ken Leong Chin},
  journal={Seminars in thrombosis and hemostasis},
  year={2015},
  volume={41 2},
  pages={
          195-207
        }
}
The commercially available non-vitamin K antagonist oral anticoagulants (NOAC) are an emerging therapeutic class, which includes dabigatran, rivaroxaban, apixaban, and edoxaban. Dose adjustment of the NOAC currently takes into account the presence of particular patient characteristics that may alter NOAC concentrations. These characteristics include the presence of renal impairment and concomitant drugs affecting proteins involved with the transport and metabolism of the NOAC. NOAC… CONTINUE READING

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 121 REFERENCES

Development of a criterion to quantify forgiveness

P Assawasuwannakit, B Rhiannon, SB. Duffull
  • Available at: http://www. paganz.org/abstracts/development-of-a-criterion-to-quantifyforgiveness/. Accessed November
  • 2014